As per the Clinical Practice Guideline for Lung Cancer in Japan (published on November 2019)7, ceritinib is recommended as the first-line therapy (PS 0–1) for patients with ALK+ NSCLC (recommendation grade 2B). This evidence concerns the gene ALK and non-small cell lung carcinoma.